Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is December 19, 2025, covering a share repurchase executed on December 18, 2025. The transaction was conducted through BNP Paribas SA as part of an existing non-discretionary buyback programme announced on September 30, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial statements. Key metrics for the transaction are as follows:
- Shares Purchased: 235,000 ordinary shares.
- Price Range: Lowest price paid was 1,797.50 GBp; highest price paid was 1,820.00 GBp.
- Average Price: Volume-weighted average price (VWAP) was 1,810.34 GBp.
- Treasury Holdings: Following this purchase, GSK holds 239,786,577 ordinary shares in treasury.
- Shares in Issue: 4,075,654,506 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 5.88% of total voting rights.
The filing does not provide data on revenue, profit, cash flow, margins, or debt levels.
Material Changes
Since the commencement of the current buyback programme on September 30, 2025, GSK has purchased a total of 14,321,733 ordinary shares. The December 18 transaction represents a continuation of this programme. There are no other material changes to the company's financial position or operations disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section of GSK's 2024 Annual Report on Form 20-F and Q3 2025 results. No specific contingencies or unusual items are detailed beyond the routine execution of the share buyback.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on September 30, 2025.
- Confirm the impact of the 5.88% treasury share holding on earnings per share (EPS) calculations.
- Review the "Risk Factors" in the 2024 Form 20-F for context on the forward-looking statement disclaimer.
- Check subsequent filings for updates on the total volume of shares repurchased under the current programme.